Vascular endothelial growth factor as a biomarker for endostatin gene therapy

Biomedicine and Pharmacotherapy

Volumn 67, Issue 6, 2013, Pages 511-515

  Braga, Marina Souza ^a,c   Turaça, Thiago Lauro ^a   Foguer, Karen ^a,c   Chaves, Karen Cristina Barbosa ^a,c   Pesquero, João Bosco ^a   Chammas, Roger ^b   Schor, Nestor ^a   Bellini, Maria Helena ^a,c  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Biomarker; Endostatin; Orthotopic metastatic model; RCC; VEGF

Indexed keywords

ENDOSTATIN; MESSENGER RNA; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; TISSUE LEVEL;

BIOMARKER; ENDOSTATIN; ORTHOTOPIC METASTATIC MODEL; RCC; VEGF;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, RENAL CELL; COLLAGEN TYPE XVIII; ENDOSTATINS; GENETIC THERAPY; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84880934755     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.04.008     Document Type: Article

References (35)

1. Dewing D., Emmett M., Pritchard Jones R. The roles of angiogenesis in malignant melanoma: trends in basic science research over the last 100years. ISRN Oncology 2012, 546927.
2. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
3. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003, 8:200-206.
4. Banks R.E., Tirukonda P., Taylor C., Hornigold N., Astuti D., Cohen D., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006, 66:2000-2011.
5. Linehan W.M., Bratslavsky M.D.G., Pinto P.A., Schmidt L.S., Neckers L., Bottaro D., et al. Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 2010, 61:329-343.
6. Vaziri S.A.J., Tavares E.L.J., Golshayan A.R., Rini B.I., Aydin H., Zhou M., et al. Differing von Hippel-Lindau genotype impaired primary and metastatic tumors in patients with clear cell renal cell carcinoma. Front Oncol 2012, 2:51.
7. Kim Y.M., Hwang S., Kim Y.M., Pyun B., Kim T.Y., Lee S.T., et al. Endostatin blocks VEGF-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002, 277:27872-27879.
8. Finley D.S., Pantuck A.J., Belldegrun A.S. Tumor biology and prognostic factors in renal cell carcinoma. Oncologist 2011, 16(Suppl. 2):4-13.
9. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010, 102(1):8-18.
10. La Thangue N.B., Kerr D.J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol 2011, 8(10):587-596.
11. Djordjevic G., Mozetic V., Mozetic D.V., Licul V., Ilijas K.M., Mustac E., et al. Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma. Pathol Res Pract 2007, 203:99-106.
12. Otrock Z.K., Hatoum H.A., Musallam K.M., Awada A.H., Shamseddine A.I. Is VEGF a predictive biomarker to anti-angiogenic therapy?. Crit Rev Oncol/Hematol 2011, 79:103-111.
13. Hanai J., Gloy J., Karumanchi S.A., Kale S., Tang J., Hu G., et al. Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol 2012, 158(3):529-539.
14. Yin G., Liu W., An P., Li P., Ding I., Planelles V., et al. Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mol Ther 2002, 5(5):547-554.
15. Ichinose K., Maeshima Y., Yamamoto Y., Kitayama H., Takazawa Y., Hirokoshi K., et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes 2005, 54(10):2891-2903.
16. Digtyar A.V., Pozdnyakova N.V., Feldman N.B., Lutsenko S.V., Severin S.E. Endostatin: current concepts about its biological role and mechanisms of action. Biochemistry (Mosc) 2007, 72(3):235-246.
17. Dhanabal M., Ramchandran R., Waterman M.J., Lu H., Knebelmann B., Segal M., et al. Endostatin induces endothelial cell apoptosis. J Biol Chem 1999, 274(17):11721-11726.
18. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001, 98(3):1024-1029.
19. Kim Y.M., Hwang S., Kim Y.M., Pyun B.J., Kim T.Y., Lee S.T., et al. J Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. Biol Chem 2002, 277(31):27872-27879.
20. Coutinho E.L., Andrade L.N.S., Chammas R., Schor N., Bellini M.H. Anti-tumor vector of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma. FASEB J 2007, 21:3153-3161.
21. Peng F., Xu Z., Wang J., Chen Y., Li Q., Zuo Y., et al. Human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models. PLOS 2012, 7(4):e34646.
22. Wang H.L., Ning T., Li M., Lu Z.J., Xi Y., Peng Q., et al. Effect of endostatin on preventing postoperative progression of distant metastasis in a murine lung cancer model. Tumori 2011, 97:787-793.
23. Braga M.S., Chaves K.C.B., Chammas R., Schor N., Bellini M.H. Endostatin neoadjuvant gene therapy extends survival in an orthotopic metastatic mouse model of renal cell carcinoma. Biomed Pharmacother 2011, 6(4):237-241.
24. Chaves K.C.B., Peron J.P.S., Chammas R., Turaça L.T., Pesquero J.B., Braga M.S., et al. Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Cancer Gene Ther 2012, 19:558-565.
25. Chaves K.C.B., Turaça L.T., Pesquero J.B., Mennecier G., Dagli M.L., Chammas R., et al. Fribronectin expression is decreased in metastatic renal cell carcinoma following endostatin gene therapy. Biomed Pharmacother 2012, 66(6):464-468.
26. Rocha F.G., Calvo F.B., Chaves K.C., Peron J.P., Marques R.F., de Borba T.R. Endostatinand interleukin-2-expressing retroviral bicistronic vector for gene therapy of metastatic renal cell carcinoma. J Gene Med 2011, 3:148-157.
27. Schips L., Dalpiaz O., Lipsky K., Langner C., Rehak P., Puerstner P., et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007, 51:168-174.
28. McDonald M., et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006, 116(10):2610-2621.
29. Zhao J., Yan F., Ju H., Tang J., Qin J. Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 2004, 204:87-95.
30. Zafirellis K., Agrogiannis G., Zachaki A., Gravani K., Karameris A., Kombouras C. Prognostic significance of VEGF expression evaluated by quantitative immunohistochemical analysis in colorectal cancer M.D. J Surg Res 2008, 147(1):99-107.
31. Feldman A.L., Tamarkin L., Paciotti G.F., Simpson B.W., Linehan W.M., Yang J.C., et al. Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res 2000, 6:4628-4634.
32. Murukesh N., Dive C., Jayson G.C. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010, 102:8-18.
33. Bellini M.H., Malpighi T.F., Calvo F.B., Miranda A.R., Spencer P.J., Cichy M.C., et al. Immobilized kidney 28-kDa endostatin-related (KES28kDa) fragment promotes endothelial cell survival. Am J Nephrol 2010, 31:255-261.
34. Qiao Z.K., Li Y.L., Lu H.T., Wang K.L., Xu W.H. Expression of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in renal cell carcinoma. World J Surg Oncol 2013, 11:1.
35. Hajitou A., Grignet C., Devy L., Berndt S., Blacher S., Deroanne C.F., et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J 2002, 16(13):1802-1804.